Serum procalcitonin concentration in patients with Kawasaki disease

Journal of Infection

Volumn 48, Issue 2, 2004, Pages 199-205

  Okada, Yasunori ^a   Minakami, Hisanori ^b   Tomomasa, Takeshi ^a   Kato, Masahiko ^a   Inoue, Yoshinari ^a   Kozawa, Kunihisa ^c   Kimura, Hirokazu ^c   Morikawa, Akihiro ^a  

^a GUNMA UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c GUNMA PREFECTURAL INSTITUTE OF PUBLIC HEALTH AND ENVIRONMENTAL SCIENCES   (Japan)

Author keywords

C reactive protein; Coronary aneurysms; Kawasaki disease; Procalcitonin

Indexed keywords

C REACTIVE PROTEIN; PROCALCITONIN;

ARTICLE; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; CHILD; CONTROLLED STUDY; CORONARY ARTERY ANEURYSM; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; FEMALE; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PREDICTION; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; SYSTEMIC DISEASE; VIRUS INFECTION;

EID: 1642464838     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2003.08.002     Document Type: Article

References (27)

1. Assicot M, Gendrel D, Carsin H. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993;341:515-582.
2. Le Moullec JM, Jullienne A, Chenais J, et al. The complete sequence of human preprocalcitonin. FEBS Lett 1984;13: 93-97.
3. Gendrel D, Bouhoun C. Procalcitonin, a marker of bacterial. infection. Infection 1997;25:133-134.
4. Dandona P, Nix D, Wilson MF. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994;79:1605-1608.
5. Nylen ES, Whang KT, Snider Jr. RH. Mortality is increased by procalcitonin and decreased by antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med 1998; 26:1001-1006.
6. Gendrel D, Raymond J, Coste J, et al. Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs. viral infections. Pediatr Infect Dis J 1999;18:875-881.
7. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974;54: 271-276.
8. Rowley AH, Wolinsky SM, Relman DA, et al. Search for highly conserved viral and bacterial nucleic acid sequences corresponding to an etiologic agent of Kawasaki disease. Pediatr Res 1994;36:567-571.
9. Cunningham MW, Meissner HC, Heuser JS, Pietra BA, Kurahara DK, Leung DY. Anti-human cardiac myosin autoantibodies in Kawasaki syndrome. J Immunol 1999;163: 1060-1065.
10. Falcini F, Trapani S, Turchini S, et al. Immunological findings in Kawasaki disease: an evaluation in a cohort of Italian children. Clin Exp Rheumatol 1997;15:685-689.
11. Hatherill M, Tibby SM, Sykes K, Turner C, Murdoch IA. Diagnostic markers of infection: comparison of procalcitonin with C reactive protein and leucocyte count. Arch Dis Child 1999;81:417-421.
12. Mangge H, Kenzian H, Gallistl S, et al. Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum 1995;38:211-220.
13. Dajani AS, Bisno AL, Chung KJ, et al. Diagnostic guidelines for Kawasaki disease. Am J Dis Child 1990;144:1218-1219.
14. Emmanouilides GC, Riemenschneider TA, Allen HD, Gutgesell HP. Moss and Adames' Heart Disease in Infants, Children, and Adolescents: Including the Fetus and Young Adult, 5th ed. Baltimore: Williams and Wilkins; 1995. p. 1390-1399.
15. Eberhard OK, Haubitz M, Brunkhorst FM. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum 1997;40:1250-1269.
16. Barron KS, Shulman ST, Rowley A, et al. Report of the National Institutes of Health Workshop on Kawasaki disease. J Rheumatol 1999;261:170-190.
17. Okano M, Thiele GM, Sakiyama Y, Matsumoto S, Purtilo DT. Adenovirus infection in patients with Kawasaki disease. J Med Virol 1990;32:53-57.
18. Okano M. Kawasaki disease and human lymphotropic virus infection. Curr Med Res Opin 1999;15:129-134.
19. Leung DY. Kawasaki disease. Curr Opin Rheumatol 1993;5: 41-50.
20. Dhillon R, Clarkson P, Donald AE, et al. Endothelial dysfunction late after Kawasaki disease. Circulation 1996; 94:2103-2106.
21. Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. J Pediatr 2000;137: 177-180.
22. Beiser AS, Takahashi M, Baker AL, Sundel RP, Newburger JW. A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group. Am J Cardiol 1998;81:1116-1120.
23. Lin CY, Lin CC, Hwang B, Chiang B. Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor alpha among patients with Kawasaki disease. J Pediatr 1992;121: 924-926.
24. Koyanagi H, Yanagawa H, Nakamura Y, Yashiro M. Serum C-reactive protein levels in patients with Kawasaki disease: from the results of nation-wide surveys of Kawasaki disease in Japan. Acta Paediatr 1997;86:613-619.
25. Nijsten MW, Olinga P, The TH, et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med 2000;28:458-461.
26. de Werra I, Jaccard C, Corradin SB. Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptor, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med 1997;25:607-613.
27. Monneret G, Pachot A, Laroche B, Picollet J, Bienvenu J. Procalcitonin and calcitonin gene-related peptide decrease LPS-induced TNF production by human circulating blood cells. Cytokine 1999;12:762-764.